Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

428 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of NAPPA is to develop new models to improve our understanding of how children process ('metabolise') penicillins, to help us discover if we can improve the dosing regimens used for children in the future. The study population will involve children and neonates who need a penicillin antibiotic as part of their normal National Health Service (NHS) care, and who also need blood tests or intravenous access. Therefore the antibiotic study can be done without the need for any extra invasive procedures, and there will be no change to the medication therapy received by participants. In addition, NAPPA will evaluate whether it is feasible to measure antibiotic levels on a tiny drop of blood put onto absorbent paper ("dried blood spot"). This allows the sample to be stored and tested later on. NAPPA will compare the level of the antibiotic using this method with the level measured in the usual way, to show if this is a reliable method that could be used routinely in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TINN Pharmacokinetics (PK) Study Treat Infections iN Neonates

NCT01319435

Pharmacokinetics of Ciprofloxacin in Neonates

COMPLETED PHASE1

Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates

NCT00873327

Sepsis

COMPLETED PHASE1

An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants

NCT00942149

Sepsis

COMPLETED PHASE1

Neonatal Antimicrobial Resistance and Outcome

NCT05743816

Neonatal Infection

UNKNOWN

Oral Amoxicillin and Cephalexin PK/PD in Neonates

NCT04916951

Neonatal Infection

ENROLLING_BY_INVITATION PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paediatric Antimicrobial Pharmacokinetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amoxicillin

Group subdivided into age categories:

Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)